Cardiorenal syndrome: Pathophysiology and treatment

Current Cardiology Reports

Volumn 15, Issue 7, 2013, Pages

  Shchekochikhin, Dmitry ^a   Schrier, Robert W ^b   Lindenfeld, Joann ^b  

^a PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY   (Russian Federation)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Arterial underfilling; Cardiorenal syndrome; CRS; Heart failure; Ultrafiltration; Worsening renal function

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGIPRESSIN; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; DOPAMINE; FUROSEMIDE; GLYCERYL TRINITRATE; INOTROPIC AGENT; LEVOSIMENDAN; LOOP DIURETIC AGENT; METOLAZONE; MILRINONE; MINERALOCORTICOID ANTAGONIST; NESIRITIDE; NITROPRUSSIDE SODIUM; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TOLVAPTAN; VASOACTIVE AGENT; VASODILATOR AGENT; VASOPRESSIN ANTAGONIST; CARDIOTONIC AGENT;

ACUTE HEART FAILURE; ARTICLE; CARDIORENAL SYNDROME; CENTRAL VENOUS PRESSURE; COMBINATION CHEMOTHERAPY; CONGESTIVE CARDIOMYOPATHY; CONTINUOUS INFUSION; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MEGADOSE; DRUG SAFETY; GLOMERULUS FILTRATION RATE; HEART FAILURE; HUMAN; KIDNEY DYSFUNCTION; LOW DRUG DOSE; MONOTHERAPY; NEUROENDOCRINE SYSTEM; NONHUMAN; OPTIMAL DRUG DOSE; PREVALENCE; PROGNOSIS; RENAL PROTECTION; SODIUM RETENTION; SURVIVAL RATE; SYSTOLIC HEART FAILURE; THERAPY EFFECT; THERAPY RESISTANCE; ULTRAFILTRATION; VASOCONSTRICTION; WATER RETENTION; METHODOLOGY; PATHOPHYSIOLOGY; REVIEW;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIO-RENAL SYNDROME; CARDIOTONIC AGENTS; DIURETICS; HUMANS; PROGNOSIS; ULTRAFILTRATION; VASODILATOR AGENTS;

EID: 84877877152     PISSN: 15233782     EISSN: 15343170     Source Type: Journal    
DOI: 10.1007/s11886-013-0380-4     Document Type: Article

References (68)

1. National Heart Lung Blood Institute: NHLBI Working Group. -cardiorenal connections in HF and cardiovascular disease - august 20, 2004. Available at http://www.Nhlbi.Nih.Gov/meeting/workshops/cardiorenalhf-hd.Htm.
2. Liang KV, Williams AW, Greene EL, Redfield MM. Acute decompensated HF and the CRS. Crit Care Med. 2008;36:S75-88.
3. Bongartz LG, Cramer MJ, Doevedans PA, Joles JA, Braam B. The severe CRS: 'Guyton revisited'. Eur Heart J. 2005;26:11-7. (Pubitemid 40221118)
4. Heywood JT. The CRS: lessons from the adhere database and treatment options. Heart Fail Rev. 2004;9:195-201. (Pubitemid 40521281)
5. Boerrigter G, Burnett Jr JC. CRS in decompensated HF: prognostic and therapeutic implications. Curr Heart Fail Rep. 2004;1:113-20.
6. Bock JS, Gottlieb SS. CRS: new perspectives. Circulation. 2010;121:2592.
7. Ronco C, Haapio M, House AA, et al. CRS. J Am Coll Cardiol. 2008;52:1527.
8. Schrier RW. Role of diminished renal function in cardiovascular mortality: marker or pathogenic factor? J Am Coll Cardiol. 2006;47:1-8. (Pubitemid 43005157)
9. Linden RJ, Kappagoda CT. Atrial receptors and renal blood flow. In: Linden RJ, Kappagoda CT, editors. Atrial Receptors. Cambridge: University Press; 1982. p. 235-9.
10. Packer M. Neurohormone interaction and adaptations in congestive HF. Circulation. 1988;77:721-30.
11. Sarraf M, Masoumi A, Schrier RW. CRS in Acute Decompensated HF. Clin J Am Soc Nephrol. 2009;4:2013-26.
12. Schrier RW. Body fluid volume regulation in health and disease: a unifying hypothesis. Ann Intern Med. 1990;113(2):155-9. (Pubitemid 20218633)
13. Blankstein R, Bakris GL. Renal hemodynamic changes in HF. Heart Fail Clin. 2008;4:411-23.
14. Schrier RW, Abraham WT. Hormones and hemodynamics in HF. N Engl J Med. 1999;341:577-8. (Pubitemid 29384167)
15. Weber K. Mechanisms of disease: aldosterone in chronic HF. N Engl J Med. 2001;345:1689-97. (Pubitemid 33126826)
16. Cohn JN, Levine TV, Olivari MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive HF. N Engl J Med. 1984;311:819-23. (Pubitemid 14035089)
17. Kramer RS, Mason DT, Braunwald E. Augmented sympathetic neurotransmitter activity in the peripheral vascular bed of patients with congestive HF and cardiac norepinephrine depletion. Circulation. 1966;33:629-34.
18. Schrier RW, Berl T, Anderson RJ. Osmotic and nonosmotic control of vasopressin release. Am J Physiol. 1979;236:F321-32.
19. Schrier RW. Blood urea nitrogen and serum creatinine: not married in HF. Circ Heart Fail. 2008;1(1):2-5.
20. Ludwig C. Lehrbuch d. Physiol, 2nd edition, 1861.
21. Winton FR. The influence of venous pressure on the isolated mammalian kidney. J Physiol. 1931;72(1):49-61.
22. Mullens W, Abrahams GS, Francis GS, et al. Importance of venous congestion for worsening renal function in advanced decompensated HF. J Am Coll Card. 2009;53(7):589-96.
23. Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol. 2009;53(7):582-8.
24. Mullens W, Abrahams Z, Skouri HN, et al. Elevated intraabdominal pressure in acute decompensated HF. A potential contributor to worsening renal function? J Am Coll Cardiol. 2008;51(3):300-6.
25. Kirsch AJ, Kayton M, Hensle TW, et al. Renal effects of CO2 insufflation: oliguria and acute renal dysfunction in a rat pneumoperitoneum model. Urology. 1994;43:453-9. (Pubitemid 24125983)
26. Ezekowitz J, McAlisher FA, Humphries KH, et al. The association among renal insufficiency, pharmacotherapy, and outcomes in 6,427 patients with HF and coronary artery disease. J Am Coll Cardiol. 2004;44(8):1587-92. (Pubitemid 39369790)
27. Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J. High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated HF: a report from the ADHERE database. J Card Fail. 2007;13(6):422-30. (Pubitemid 47179911)
28. Aronson D, Mittlemann MA, Burger AJ. Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated HF. Am J Med. 2004;116(7):466-73. (Pubitemid 38388616)
29. Filippatos G, Rossi J, Lloyd-Jones DM, et al. Prognostic value of blood urea nitrogen in patients hospitalized with worsening HF: insights from the Acute and chronic therapeutic impact of a vasopressin antagonists in chronic HF (ACTIV in CHF) study. J Card Fail. 2007;13(5):360-4. (Pubitemid 46977793)
30. Ismailov RM, Goldberg RJ, Lessard D, Spencer FA. Decompensated HF in the setting of kidney dysfunction: a community-wide perspective. Nephron Clin Pract. 2007;107(4):c147-55.
31. Gotsman I, Zwas D, Planer D, Admon D, Lotan C, Keren A. The significance of serum urea and renal function in patients with HF. Medicine (Baltimore). 2010;89(4):197-203.
32. Brandimarte F, Vaduganathan M, Mureddu GF, et al. Prognostic implications of renal dysfunction in patients hospitalized with HF: data from the last decade of clinical investigations. Heart Fail Rev. 2012. doi: 10.1007/s10741-012-9317-z. Excellent review on epidemiology and prognosis in CRS.
33. Gottlieb SS, Abraham W, Butler J, et al. The prognostic importance of different definitions of worsening renal function in congestive HF. J Card Fail. 2002;8(3):136-41. (Pubitemid 34857278)
34. Klein L, Massie BM, Leimberger JD, et al. Admission or changes in renal function during hospitalization for worsening HF predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic HF (OPTIME-CHF). Circ Heart Fail. 2008;1(1):25-33.
35. Cowie MR, Komaja M, Murray-Thomas T, Underwood J, Tiko B. Prevalence and impact of worsening renal function in patients hospitalized with decompensated HF: results of the prospective outcomes study in HF (POSH). Eur Heart J. 2006;27(10):1216-22.
36. Forman DE, Butler J, Wang Y, et al. Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with HF. J Am Coll Cardiol. 2004;43:61-7. (Pubitemid 38045917)
37. Lanfear DE, Peterson EL, Campbell J, et al. Relation of worsening renal function during hospitalization for HF to long-term outcomes and rehospitalization. Am J Cardiol. 2011;107(1):74-8.
38. • Aronson D, Burger AJ. The relationship between transient and persistent worsening renal function and mortality in patients with acute decompensated HF. J Card Fail. 2010;16(7):541-7. The difference between transient and persistent WRF for prognosis.
39. Nohria A, Hasselblad V, Stebbins A, et al. Cardiorenal interactions: insight from the ESCAPE trial. J Am Coll Cardiol. 2008;51(13):1268-74. (Pubitemid 351400890)
40. Testani JM, Coca SG, McCauley BD, Shannon RP, Kimmel SE. Impact of changes in blood pressure during the treatment of acute decompensated HF on renal and clinical outcomes. Eur J Heart Fail. 2011;13(8):877-84.
41. •• Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated HF. N Engl J Med. 2011;364(9):797-805. First randomized study on diuretics in ADHF.
42. Blair JE, Pang PS, Schrier RW, et al. Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening HF in the placebo group of the EVEREST trial. Eur Heart J. 2011;32(20):2563-72.
43. Ruggenenti P, Remuzzi G. Worsening kidney function in decompensated HF: treat the heart, don't mind the kidney. Eur Heart J. 2011;32(20):2476-8.
44. Zile MR, Bennett TD, St John Sutton M, et al. Transition from chronic compensated to acute decompensated HF:pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation. 2008;118:1433-41.
45. Jain P, Massie BM, Gattis WA, Klein L, Gheorghiade M. Current medical treatment for the exacerbation of chronic HF resulting in hospitalization. Am Heart J. 2003;145(2 Suppl):S3-S17. (Pubitemid 36207920)
46. Fauchauld P. Effects of ultrafiltration of body fluid and transcapillary colloid osmotic gradient in hemodialysis patients, improvements in dialysis therapy. Contrib Nephrol. 1989;74:170-5.
47. Lindenfeld J, Albert NM, Boehmer JP, et al. Executive summary: HFSA 2010 comprehensive HF practice guidelines. J Card Fail. 2010;16(6):475-539.
48. Shchekochikhin D, Lindenfeld J, Schrier RW. Increased Spironolactone in Advanced HF: Effect of Doses Greater Than 25 mg/day on Plasma Potassium Concentration. Cardiorenal Med. 2013;3:1-6.
49. Francis GS, Siegel RM, Goldsmith SR. Acute vasoconstrictior response to intravenous furosemide in patients with chronic congestive HF. Activation of the nuerohumoral axis. Ann Intern Med. 1985;103(1):1-6. (Pubitemid 15068490)
50. Silverstein ME, Ford CA, Lysaght MJ, Henderson LW. Treatment of severe fluid overload by ultrafiltration. N Engl J Med. 1974;291(15):747-51.
51. Constanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated HF. J Am Coll Cardiol. 2007;49(6):675-83. (Pubitemid 46205043)
52. Giglioi C, Landi D, Cecchi E, et al. Effect of ultrafiltration vs diuretics on clinical, biohumoral and haemodynamic variables in patients with decompensated HF: the ULTRADISCO study. Eur J Heart Fail. 2011;13(3):337-46.
53. •• Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated HF with CRS. N Engl J Med. 2012;367(24):2296-304. Randomized study on UF versus pharmacological approach in CRS.
54. Marenzi G, Grazi S, Giraldi F, et al. Interrelation of humoral factors, hemodynamics, and fluid and salt metabolism in congestive HF: effects of extracorporeal ultrafiltration. Am J Med. 1993;94(1):49-56. (Pubitemid 23021171)
55. Rosario LB, Stevenson LW, Solomon SD, et al. The mechanism of decrease in dynamic mitral regurgitation during HF treatment: importance of reduction in the regurgitant orifice size. J Am Coll Cardiol. 1998;32:1819-24. (Pubitemid 29010440)
56. Stevenson LW, Brunken RC, Belil D, et al. Afterload reduction with vasodilators and diuretics decreases mitral regurgitation during upright exercise in advanced HF. J Am Coll Cardiol. 1990;15(1):174-80. (Pubitemid 20034271)
57. Publication Committee for the VMAC Investigators (Vasodilatation in the Management of Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive HF: a randomized control trial. J Am Coll Cardiol. 2002;288(5):577-2002.
58. • Parissis JT, Rafouli-Stergiou P, Stasinos V, et al. Inotropes in cardiac patients: update 2011. Curr Opin Crit Care. 2010;16:432-41. Good review on inotropes in ADHF and CRS.
59. Follath F, Yilmaz MB, Delgado JF, et al. Clinical presentation, management and outcomes in the Acute HF Global Survey of Standard Treatment (ALARM-HF). Intensive Care Med. 2011;37:619-26.
60. Elkayam U, Tasissa G, Binanay C, et al. Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe HF. Am Heart J. 2007;153:98-104. (Pubitemid 44880871)
61. Leier CV, Heban PT, Huss P, Bush CA, Lewis RP. Comparative Systemic and Regional Hemodynamic Effects of D opamine and Dobutamine in Patients with Cardiomyopathic HF. Circulation. 1978;58:466-75. (Pubitemid 9006974)
62. Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med. 2005;142(7):510-24.
63. Giamouzis G, Butler J, Starling RC, et al. Impact of dopamine infusion on renal function in hospitalized HF patients: results of the Dopamine in Acute Decompensated HF (DAD-HF) Trial. J Card Fail. 2010;16:922-30.
64. Zemljic G, Bunc M, Yazdanbakhsh AP, Vrtovec B. Levosimendan improves renal function in patients with advanced chronic HF awaiting cardiac transplantation. J Card Fail. 2007;13(6):417-21. (Pubitemid 47176926)
65. • Valika AA, Gheorghiade M. Ace inhibitor therapy for HF in patients with impaired renal function: a review of the literature. Heart Fail Rev. 2012. doi: 10.1007/s10741-011-9295-6. Review on ACE inhibitors treatment in patients with CRS.
66. Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive HF during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol. 1992;70(4):479-87.
67. Oster JR, Meterson BJ. Renal and electrolyte complications of congestive HF and effects of therapy with angiotensin-converting enzyme inhibitors. Arch Intern Med. 1992;152(4):704-10.
68. Packer M. Functional renal insufficiency during long-term therapy with captopril and enalapril in severe chronic HF. Ann Intern Med. 1987;106(3):346-54. (Pubitemid 17029483)